Rat sponge implant model: a new system for evaluating angiogenic gene transfer.

Wang, He; Gordon, David G.; Olszewski, Bronia; Song, Yi; Kovesdi, Imre; Keiser, Joan A.

doi:10.3892/ijmm.6.6.645

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest dose of CI‐1023 in our study was 4×10 10 pu, this dose was selected based on our previous experience with a rat sponge implantation model (Wang et al 2000). The other dose groups were: 4×10 9 pu, 4×10 8 pu, 4×10 7 pu, 4×10 6 pu, a vehicle‐only and an AdNull (4×10 10 pu) control groups, each group contained 6 rats.…”

Section: Resultsmentioning

confidence: 99%

“…CI‐1023 (Ad GV VEGF121.10) is a replication‐deficient adenovirus vector (complete E1a − , partial E1b − , partial E3 − ) delivering human vascular endothelial growth factor‐121 gene. Previous studies by this group have established that CI‐1023 can successfully transfer human vascular endothelial growth factor121 gene, resulting in local tissue expression of vascular endothelial growth factor protein with angiogenesis‐promoting activity (Wang et al 2000). However a detailed analysis of CI‐1023 neovascularization‐promoting potency and efficacy in a clinically relevant ischaemic model is still lacking.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Dose‐Dependent Neovascularization‐Promoting Effect of Adenovirus Vector CI‐1023 in a Rat Hindlimb Ischaemic Model

Wang

Keiser

Olszewski

et al. 2004

Basic Clin Pharma Tox

View full text Add to dashboard Cite

CI-1023 (AdGVVEGF121.10) is a replication-deficient adenovirus vector (complete E1a-, partial E1b-, partial E3-) delivering human vascular endothelial growth factor-121 gene. Previous studies from this group have established that CI-1023 can successfully transfer human vascular endothelial growth factor-121 gene resulting in local tissue expression of vascular endothelial growth factor protein. The purpose of this study was to evaluate neovascularization-promoting potency and efficacy of CI-1023 in a wide dose range. In a rat hindlimb ischaemic model, we measured neovascularization-promoting effect of CI-1023 using three end-points: post mortem angiography, immuno-histochemistry and Laser Doppler scanning of tissue blood perfusion. Neovascularization-promoting activity of CI-1023 over the dose range of 4 x 10(6) pu-4 x 10(10) pu was evaluated. Our data demonstrated an obvious dose-dependent effect between 4 x 10(6) pu-4 x 10(8) pu. The neovascularizing effect is somewhat plateaued at the levels between 4 x 10(8) pu and 4 x 10(10) pu. We conclude CI-1023 is a potent neovascularization-promoting compound, with a dose-dependent effect between 4 x 10(6) pu-4 x 10(8) pu in the rat hindlimb ischaemic model.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Dose‐Dependent Neovascularization‐Promoting Effect of Adenovirus Vector CI‐1023 in a Rat Hindlimb Ischaemic Model

Wang

Keiser

Olszewski

et al. 2004

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

Quantitative Angiogenesis Assays in vivo – A Review

et al. 2004

View full text Add to dashboard Cite

The development of agents that target tumour vasculature is ultimately dependent on the availability of appropriate preclinical screening assays. Several quantitative angiogenesis assays exist, each with its own unique characteristics and disadvantages. In this review we discuss some of the commonly used assays, their methodological pitfalls and current use. The corneal micropocket and the CAM assay are well established. However, the matrix-implant assays have the potential advantage of replicating the hypoxic tumour microenvironment, thus making them suitable for the study of tumour angiogenesis. The ideal quantitative angiogenesis assay does not exist and the use of two complimentary quantitative assays, such as a matrix implant assay and a microcirculatory preparation like the CAM or corneal micropocket assay, provides the best compromise. Newer models like the hollow-fibre assay are being developed and older ones refined. Assay systems should reflect distinct disease processes. Thus it is appropriate to develop assays that study exclusively pro- or anti-angiogenic compounds or anti-vascular agents. Criticisms of currently available screening systems are that the predictive value of current screening systems remains to be established as anti-angiogenic agents are still in clinical development. Anti-angiogenic agents are likely to be most effective as chronic therapy for remission maintenance in the metastatic setting or as adjuvant therapy in patients at high risk of relapse, an important clinical aspect not addressed in animal models of tumour angiogenesis. Histological analysis still provides the most detailed information on in vivo angiogenesis. However, angiogenesis is a dynamic process and assays that permit continuous monitoring of the angiogenic response and provide information on the physiological characteristics of new vessels will be distinctly advantageous over older systems. The development of non-invasive techniques for quantitation of angiogenesis will greatly facilitate this process.

show abstract

Expressão do fator de crescimento endotelial vascular (VEGF) e seus receptores VEGFR-1 e VEGFR-2 durante o início da gestação em camundongos.

Silva¹

View full text Add to dashboard Cite

Rat sponge implant model: a new system for evaluating angiogenic gene transfer.

Cited by 3 publications

References 0 publications

Dose‐Dependent Neovascularization‐Promoting Effect of Adenovirus Vector CI‐1023 in a Rat Hindlimb Ischaemic Model

Dose‐Dependent Neovascularization‐Promoting Effect of Adenovirus Vector CI‐1023 in a Rat Hindlimb Ischaemic Model

Quantitative Angiogenesis Assays in vivo – A Review

Expressão do fator de crescimento endotelial vascular (VEGF) e seus receptores VEGFR-1 e VEGFR-2 durante o início da gestação em camundongos.

Contact Info

Product

Resources

About